Loading...
Docoh

Aptinyx (APTX)

Participants
Nick Smith VP of Corporate Development & IR
Norbert Riedel CEO
Ashish Khanna CFO & CBO
Andy Kidd President & COO
Kathryn King SVP of Clinical Development
Harald Murck VP of Medical & Pharmacovigilance
Myles Minter William Blair
Charles Duncan Cantor Fitzgerald
Laura Chico Wedbush Securities
Marc Goodman SVB Leerink
Ritu Baral Cowen
Gary Nachman BMO Capital Markets
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Good afternoon, and welcome to the Aptinyx First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Following the formal remarks, we will open up the call for your questions. Please be advised that the call is being recorded at the Company's request. At this time, I would like to turn the call over to Nick Smith, Vice President of Corporate Development and Investor Relations at Aptinyx. proceed. please Nick,

Nick Smith

Good us Operator. first and you thank XXXX Thank today's afternoon, conference joining results. on and Aptinyx's call for financial you, operating everyone, to quarter discuss

business the Officer press followed Khanna, highlights review website. Our who by results. on Norbert will Ashish Executive call, and our Officer, our our financial will and review describing results our Today is available business Chief on release Business now financial our Chief Officer, Financial Riedel, Chief and clinical progress,

In of and the Kathryn for Pharmacovigilance addition, Vice Chief Operating King, our and Kidd, our us Andy President and Q&A our Officer portion Senior Clinical Murck, Medical with and Vice Harald of of President the President are Development; call.

everyone call of this actual uncertainties made risks statements remind differ Before Reform that that Securities statements will materially. involve only cause Any obligation forward-looking meaning the the statements. we of company's to we conference forward-looking begin, release update the disclaim within Private Act and can statements Litigation during like which include are to I'd XXXX, results factors financial issued subsequent forward-looking and the and as the with risk over filings Norbert, to any this statements you. results in forward-looking see the afternoon Please and current these of SEC. made in disclaimer our today, to

Norbert Riedel

you We you, the time taking Thank join everyone. to on and appreciate good call. Nick us today's afternoon,

extensive And progress and her to our Dr. stage development development. would Miller into experience join brings programs. Related our I medical Board. recently you us clinical leadership, academic like clinical into excited of the research we we delve programs, clinical Board Directors. have to to announced John share we of to clinical have Before clinical in to that later our as are appointment John and we with our

weeks to a business of our since has our important programs. progress update four it each have we few made only last been Although call,

Phase three one X one and have painful DPN, currently fibromyalgia, we recall, in in impairment. underway clinical you As studies cognitive in one

diligently I'm enrollment executing very been studies report have And is on teams that this study. in to patient well. Our each of tracking these happy

We with positive Phase intended on registration indication. PTSD focused design developments PTSD to of our study supportive with keenly weeks of Xb have come moving These program toward for the a in in be initiation few also been a particular, have past program. number this our

Society of in our significantly reliable index or a effect So study I exploratory additional for those change defined as patients with will start reliable XX initial Biological proportion on Of a presented the annual by of for driven which randomized, as consistent is XX X or and provide In These updates effect from from at late CAPS-X PTSD we purely variability. score Stage our NYX-XXX. Total Psychiatry design, treatment improvement the in of real We determining April, meeting compared of a was an clinically is patients data a SOBP. milligram metric opposed the that the parallel points greater the week double next of period reported placebo. recognized to treatment The with more and insights most blind, included change study, group, informative study. a have four all achieved data to

NYX-XXX Also the to Our for are SOBP trauma, since presentation parameters we also patient's on input agency percentage the for parameters. in the highlighted accordingly. of was path score across And the of the review XX the us study. time planned CAPS-X Type that protocol meeting, the a group finalizing Total milligram with valuable when baseline in study on the the key imbalances PTSD accounting FDA to groups improvement process which treatment for design a meeting of in reinforce NYX-XXX It during provided PTSD. the positive Phase These variety discuss by upcoming statistically significant in development in the therapeutic we confidence additional for in a our the placebo a met with from C of April, and late potential separated the of analyses the margin. study future details Xb of our

the have we at dosing to of our high to a level this with CAPS-X. to-date, parallel As in placebo primary out the NYX-XXX study design X XX randomized in evaluation weeks score compared a public will involve Total in laid daily presentations of as endpoint. of

the the proceeding NDA. positive, studies believe of in be will if accordingly, has controlled that for required design the and we support agency by with are the two We one well data as an potential consideration study the of

that course, in the of commence of design continue the on review provide to review the study anticipate will the following be by data. that study the and study completion and agencies will details MFFO Xb this Of plan this to half greater year. we of Phase We the second

X on study. studies data first XXXX.We appreciate diabetic of the goals from fibromyalgia. towards both pain and development and painful two that clinical in Let's investigator half report sites continued the chronic the made be neuropathy in enrollment involved have am which to progress in briefly Phase in excellent in to track and our peripheral NYX-XXXX across indications readouts glad in we continue patients engagement this we discuss projected and in I is our

of period. signal daily is milligrams and double study designed tolerability a This therapeutically in NYX-XXX of XX-week a assess placebo its randomized impairment. profile patients candidate is we with in activity patients with in NYX-XXX, approximately associated in move over bodies. first being is either NYX-XXX this XXX and treatment with cognitive recently developing This patient to of exploratory patients We Lewy detect parallel population. these is NYX-XXX enroll to a relevant expected with X is This the design receive we an to dosing to blind, to commenced of diseases. XX of study evaluated or cognitive study Parkinson's exploratory disease and our that impairment for with product the announced dementia Phase treatment Let's have time now

mechanism we data across executive over and Given NYX-XXX, second able so Ashish are now expect the of function. in characterize and pleased endpoints With be I cognitive we call am in quarter progress half memory I to in turn evaluating study multiple this attention, XXXX. far of the with the our order report study to level review will our the from to that, to results. to this financial first activity

Ashish Khanna

Norbert. Thanks,

our in the a XXXX. current we clinical X fund from As across enabling cash our XXXX by fortunate we to multiple supported operations our progress Phase be of cash make readouts programs, the We strong position. anticipate year into each are way studies along will

ended first the in we predetermined with first studies $XXX.X $X.X XXXX. future research balance were million our related collaboration development period accordingly, to $XXX associated were focused clinical cognitive The same expect with has expenses of million were the for $XX.X in compared revenues equivalents The first the the the ongoing a quarter majority and now it. to agreements on with XXXX. XXXX. research chronic contractual no conclusion. And period come collaboration million for and sheet, to with the Allergan, These agreement revenues to the our its cash at subsidiary across our impairment. pain R&D quarter cash to related we $XX.X to of million in compared spend million for Revenues $X quarter of beginning million in end and Specifically, compared same AbbVie. was

the million quarter expect turn account G&A planned studies, increase to $X.X three the same million the loss compared We as We period same our our of NYX-XXX over to of ongoing to first was million well for of throughout expenses our R&D Norbert. first now study Xb compared net expenses I'll $XX.X reported period XXXX of call on $X XXXX. as to back $XX.X million for quarter, clinical the PTSD. the Phase for in a loss in net XXXX.Finally, for in

Norbert Riedel

our focus exciting us period catalytic feel progressing within next Ashish. ongoing patients is be this our execution as will with strong months. study achieve confident time better that studies will potentially Thank need. our with of XX the to and along critically three clean us to in to milestones programs therapeutic With important our seek you, the year position initiated financial across an XX next month, we This options to PTSD for well another be for very coming Aptinyx. to enable We multiple on in clinical is

now. We questions will your to begin be taking happy

the feel much I'd As Q&A we that like keep open the we can we the next said, awaiting I it of With to PTSD mind for meeting. how our minutes in you we in still up now. questions, be are about limited study, as that talk will

Operator

question. Thank just Please your you, limit [Operator sir. to question one Instructions]

roster. Q&A all while that we participants stand-by, can So the question. the ask Please compile

line Our of first from Minter William question from Myles the Blair. comes

open. is Your line

Myles Minter

and the the congrats between specified learnings set? PTSD. is that and questions about on the first a child or like setting criteria the design? you have patients you thinking you data have correlation the want just into child analysis meeting. saw more that guess dosing incorporating Would patients XX are SOBP might milligram those something something where exclusion be when taking the I a the for thanks off with efficacy given My their events Hi, recent had traumatic data that on you one FDA be those stratify how more inclusion, now, you would that pre in for to those it enhanced the

Norbert Riedel

giving I'm going you Andy kick sense to of are That’s about how off Myles. question. Thank thinking a this you, that it with a we have point. at terrific

Andy Kidd

be question. Yes can't said, thanks, of Myles. definitive we Norbert sort this. Like Good about

excluding specific a preference trauma to finalize longer one this probably would looking more on our though, we think but once thing learning, is time say we that be specific ways with entirely other to to I we patients since study probably the can we incorporate be would design. and avoid question

I want to right only we point the now. make think that's

Myles Minter

guess then of CAPS-X trial, being definitely what would expect to of XX and Okay, be, on with that to you guess, to a think from would therapy talking I over baseline meaningful you kind improvement obvious does weeks fair a you going the X on four you're meaningful treatment, few that jive question placebo, X to I in clinically but total age with from And they obtain the stipulating? we've comment placebo over weeks like anticipate points clinically saw that enough. XX clinicians, a I the made been points also is

Norbert Riedel

think few I improvement continued expect think we other that's the to weeks Myles, Yes, well right as to factors. roughly four weeks, over as perhaps see, course eight would of I a

study I out, think in into can design obviously as more larger. again, detailed help us being study get might the that we well the which as

think I fair. that's yes, So

Myles Minter

be would meaningful X point placebo to just definitive, you'd be here? that move over threshold the clinically But agree a

Norbert Riedel

that size it's number. the see be to effect down line. we more study, forth. in pinned we're right and we're can we'd be to think specific and to exact Again, show think think I looking down design that powered probably don't that as the about the I so we'll direction, but Again, specific we

Myles Minter

congratulations John appointment. And has in great my question board. ophthalmology. That's a Miller is, on extensive the final She expertise on obviously

broader expanding the ballpark the So going something a the about this on this question one? on whether NMDA question, thinking Is ocular modulator it to at I is the you're indications? wrong does that you're look completely or into but of potentially am bake platform out

Norbert Riedel

No.

therapy in the I as the think to clinical out getting extensive as basically clinical we instrumental board John all for development and first well joining fairly having been Myles, in So medical involvement her excitement our leadership press and the way experience in academic AMD. really about that is research approved the pointed release

So terrific. that is

areas we beyond which what now, we we key receptor the shown as a for communicated are think, and John us our we go biology in But to actually makes contributor in And with be to and developing numerous there. currently go basically we scope, from sense how I help plate. see to indications other involved and time will about comes that test in look before have what I where forward extend there various are stay to when course most is the the being it. NMDA have our diseases on to

Operator

to questions to one question. again a allow ask other please participants reminder, to Once your as limit a

line Cantor Our from of Duncan question the Charles from comes next Fitzgerald.

open. Your is line

Charles Duncan

are to Yes, it mentioned follow you meeting color, it progress any in thank for team I'm positive on I the C to program or of agency's to awareness on challenge wondering, thoughts Type and you, read you recently the did the be you or provide I any of that point Norbert has if have have did the I was feature guess quarter. you new and that results? want the that PTSD on NMDA ask of meeting. differentiated want the could Can PTSD a that you're I wanted having there congrats the up NMDA key know you XXX. I'm opportunity regard given and PTSD the to? kind the you And been any Thanks. that to the some positive there minutes, I but consider takeaways wondering trial of mechanism design waiting XXX then with positive, out a question,

Norbert Riedel

you thank terrific, So Charles.

look positive PTSD is and clear a approaches to there support very acknowledgement in ways was choices. we finding very So of that Type in limited is to is and meeting actually much better. think I a that mechanisms PTSD the frequent sufferer C significant there have for new which new are think from recognition And serve I challenge that

news am at communicate the And is as much look before right how details we I what and going there it. think the and study is of was line what we like. positive Phase pointed pleased But communicated in we very be study that outline what roughly that will indeed, our to communicated had also that about I it as out, that Xb before go we will that is in outlined time. we will to with

I reasons. results, encouraging that's MDMA very very, for of number the actually think On a

tolerability about been First, if about reset very a to and in that plasticity and I be it lines, treatment basically, cognitive MDMA is the most established difference have believe mechanism to mechanisms meaningful is compounds and liked with who MDMA plasticity superb I comes it importantly, makes now works PTSD healthy that the is includes profile or And like definition we of active receptors in along patients. I of treated pretty it’s fully with what much placebo we safety that fully our what and very either actually terms of volunteers it And three network. the that that CBT. those here I looks our large of have say, enhancement and that changes, as compared are patients need of and that would along as have to our in profile numbers of mechanism, with a the shown,

excited differentiates and about go us we and why we how that think indications. I So about really where go about that's PTSD we are other and

Charles Duncan

part I but question. I appreciate you was my hoping connection, you'd Thanks, mechanistic taking make Norbert. and that single multi

Norbert Riedel

let now. I will you you If in have another one, take it

Charles Duncan

I have people to I on respectful want other be the many, of the call. but

Norbert Riedel

All when time right. we end get Maybe have at the you back in the queue.

Charles Duncan

Yes.

Norbert Riedel

you. Thank

Operator

from comes Securities. of from line question next the Our Joon Lee Truist

open. is line Your

Unidentified Analyst

XXX [Indiscernible] think be give taking relate a suffering questions. how what that trial from for you PTSD, us Hello, benefit Thank severe bigger of having longer for PTSD saw could on XXX, to PTSD for Phase extract on military larger there in civilian also severe Joon. color moderate if PTSD regarding will And who a be or then of period? proportion enrolling And where and we our versus the PTSD do baseline? effect the you for advanced DPN XXX patients, patients will these that? simulate And in on a to some you patients Xb

Norbert Riedel

see how this we Okay, can a let's team. tackle as

of is importance. course changes point from the how looking going starts in to changes. disease So centrally to we at are does But established your of over get and time of relates comment to question Charles of in more the of made I'm just itself that a and manifests the I actually the And patients view neuropathy part the disease. with that plasticity DPN longer periphery. perceived the it pain to duration in study DPN this cause

have patients disease those the longer that a it a that So earliest disease. why from we have Xb suffered of pronounced saying a longer patients study perception sense actually makes perfect makes mechanistically is on the had have time for on brain, sense have by the covenant to pain have that which their of study duration in more manifestation we focused done it and be issues advanced mechanistically, processing the rely Phase

I think question. that answers your DPN

but said Andy we me in comment of not the to have as of our minutes as that position the and I to further patient cannot meeting of finalized design. first and parameters a it give files will already, such study, on Let size numbers PTSD until actually all, we and as try the have are relates of and designed study

Andy Kidd

Norbert. thanks, Yes,

calls we enroll still I try population think apply. heading think as at broad general our so reiterate inclusion that the possible we before study be to the this make as entire to are representative philosophy the design to prior on and But patient population design. we thing I can’t would think the you PTSD more had those of obviously, a I we will one to is in of exclusion because point we the a comment as that plan can And will still that we point forth, once finalize we did and include said can outlined fairly be group. we that beyond more comment specific the we study criteria a we PTSD patient direction there some

Unidentified Analyst

And do model should quickly would expression? this where Parkinson’s? less you translate benefit NMDA acute expect -- injury a the where disease you to NHP think you. setting Thank How of this on receptor very

Norbert Riedel

potential you right? address And goes view about Okay. You're have following If how asking I'm therapeutic there please. in up, in to benefits going impairment. understand I about, to guess Harald the If data I few actually mind, question actually a that question. our wouldn't as of cognitive question, your mechanistic XXX are Harald

Harald Murck

dementia, combine a basically similar Yes, is that increase the and the with α-synuclein us observations one really which which the of of basis to an of And number we on pathophysiology, indication course, of in been led bodies is animal NMDA both α-synuclein have disease our see these disorders. down the a based Parkinson's Lewy from compound of first models, a dementia receptor. of foremost there's they data that has regulation known which on an of NMDA effect preclinical have NYX-XXX, actually it as to a we that studies regulates of leads demonstrated which up receptors own

say pathology. a regulation are to, expect have the beneficial you induced So basically effect is but we which α-synuclein and by want way, that to see to this, working of clinical been in the strong reversing hypothesis mechanistical if very by we

As a based in it I of animal is data. think as scientist, as gets this the space But working strong hypothesis is this on science.

Operator

comes Securities. question Wedbush line next of Our Chico from from the Laura

Your line is open.

Laura Chico

Good question. afternoon, and like thanks it XXX focus try to and I taking will the definitely to on just ask for one. one study. And the fibromyalgia to I

was there sensitivity fibromyalgia So scores. that study transitive NRS recently to published whether on relationship examine

the if So different controlling it about us be of b on were looking was XXX, the U.S. much. and weather variable regions. thoughts interesting just up the that you Phase for to might And powering a scores. your geography the to to just also subjects NRS on for diverse sampling but any pretty nearly And how remind could you very across talk X a be sensitive deemed endpoint? maybe primary study having the just study, in that Thanks wondering assumptions ended here two-thirds worse we've got for at

Norbert Riedel

question Great. Thanks, thoughts? take Laura. that you and to share your Kathryn, would like

Kathryn King

Yes, and our of think kind we've you as wide spread a noticed, of I sites. geographic got diverse

say it fibromyalgia bring look for a also, general are we I want as across we impact, any respect expect to in something by still variety we would certainly this account impact but that interpretable we a it, therapy to wide shouldn't that enrollment and experienced that sites, dramatically for So guess results that patients, to results, have if market well. of it our just that is with with should could I sense. think also to

be So it to it'll as interesting explore we go.

Norbert Riedel

that I also not the uncommon and has with been that with spread to diabetic to noted Kathryn agree this kinds powering believe neuropathy other have fibromyalgia. geographic cope and we think chronic study I appropriate, to it. think pain it's or in I And, unique of I

Operator

Marc Goodman from Our line Leerink. comes from next the of SVB question

open. Your line is

Marc Goodman

us mean, process? know, give be of Hi Norbert, so I I are any on enrollment the mean, anything I we helpful XXX for the far in in hoping you some Thanks. where the was color you could would drop studies, color type out

Norbert Riedel

that parameters, on we basically design details can Great, and don't first Marc. you, I XXXX. to you best offer with out as enrollment we Thank communications I out timeline, confirming remarks, numerous and including previous our in is that track account as and specific of enrollment with my half delight much alike. size made read as actually studies share take And my into comments on the we them any that well from prepared the respect the of with to of we weight studies. are dropout our data in as

we And that ongoing is as pleased so out to our the and to the you that's typically conforming where parameters are from I studies study. we and they set likely But are discussing trial satisfied actually studies. can how time have what this with the deduct of to be limited

So good. far, so

Marc Goodman

and And just just one that think Parkinson's Lewy for clarification do things taking this was half? groups of the will is a the specified and this enrolling, trying are working? patients he half you How total, in either? it you both be Are that in you're to XXX all on pre said and bodies I then comers

Norbert Riedel

in specifying way. pre a particular we're Marc, not or stratifying

to And so patients disease entry it likely the the Parkinson's, three Parkinson's likely mixture dementia know about probably a of dementia we diagnosed with about that into numbers patient all clinical MCI, what seek it's are on as and and which and bodies. trials Lewy based be of to of will extent

we expect So stratification. got a any but yes, we mixture haven't

Marc Goodman

Thank you.

Operator

Ritu Cowen. line the Baral from of Our next question comes from

open. line is Your

Ritu Baral

you versus you two huge, X guys. I the down question. nailed think address identical? want X the as of up. about of populations you you study. is you have to Do that you of study the then [Indiscernible] Phase that taking the understand X, sort studies X that? for Good are generally PTSD might haven't number that follow separately? design afternoon, think alignment FDA Could But in Thanks the Phase might X can Phase very final got essentially a And I've be investigate quick that sort study

Andy Kidd

Yes, it's Xb clarify, Ritu sure. for that study. the kind of should And address Phase we

Type not an meeting. And had Phase meeting. so end C a X was of we've This

when is that, study, matter we a that we it a believe I to this very could of But be be to positive study say remarks like, say. possibility. would the that that's I and We one think potentially and a Norbert certainly matter alive case, support And his would until study what as the study. FDA wait have used we part what think the for future look minutes. anymore. FDA expect But have FDA, study said the pivotal data registration would on comment review. design be that's what that If much we pivotal of to we could in want until to then is design finalized further exactly we complete for

Ritu Baral

looking competitors function. But be more of off wondering communication I with based prioritize study, on guess Got And your or opinion. on that's payroll cognitive cognition I'm at seem you if at endpoints executive and multiple three? How you're mentioned looking different guidance transferring Some your or Parkinson's you it. do memory then of executive focusing of to function. XXX those just mechanisms cognitive also

Norbert Riedel

So point out, finding it's a exploratory you studies. first of as all, signal

We confirm have the other talking very across function indication have to next for we from to the information neurocognitive we then cognition can in the active what that compound for. just from And no opportunity be across So learning. look about that like domains are would in multiple a much order. studies study then we preclinical executive as be targeted to more we we that that's use XXX actually basically the looking results prioritized specifically done give it to the to we so we much know is us done particular want want what

to So se. particular give want out endpoint per be we border you any without to opportunity definitely prioritizing add Khanna? Anything. here the

Ashish Khanna

Yes, so were the see you're maybe an executive may that don't to attention. not of on made improvement have what referring they informed I expectation. We that of that to perhaps data just think may capacitor sort comment, a and on has that expecting inform function more exactly know much

you really model preclinical if in data we in think, robust our non-human primates, domains. MPTP cognitive generated findings that the across recall I achieve a model, relevant

have we utilizing are tells. And why will so see the in expectation. and domains such different areas data cognitive no that's all cognitive the the endpoints we studying we these of prior different different and what And tasks

Ritu Baral

Great, thanks question. taking for the

Operator

Our from Gary the Markets. BMO line from comes Capital Nachman of next question

open. is line Your

Gary Nachman

Good afternoon. Thanks.

that remind you're on it bodies Just the of data the you would following us that dementia, down think cognitive Thanks. outcome at indications chance have there's inform up some you the once on change could XXX, dose you in road, why just depending the using your Lewy milligram what and just hand? potentially XX point are dose, other while study? And dysfunction to then a Parkinson's focus that initially do you need on on the

Norbert Riedel

Great. Thank you, Gary.

preclinical part to do sure work compounds. I the to first ranges that in And dose think then most in of presence where the been we or at have the would on effective have in Phase much right extensive of looked in models, ranges have done And make of So I correlate take in in question. the X I goal satisfaction fibromyalgia I year very we at. pretty we we picking brain see healthy mentioned effective can dose be looking we that target, dose volunteers preclinical DPN confirm PTSD. the before the we the our we right of now your to Gary, and studies dose with can that predicting level say, full most exposure in the compound

doubt, signal do just exploratory there So those dose there's requirements that study. study benefit and in our also to ranging the part the well, would a on without like second dose a the will of do funding have. to top level the pretty exploratory we reason And own agency want to that we high this will here do the studies, But milligram for of we question. is XX confidence as that is have future right you But first changing was because this see. your specifically then no dose it with of burden which

Gary Nachman

dementia the indication? Parkinson's Yes, cognitive on is other and going have Lewy you'll for to just data dysfunction inform that bodies potential how Yes, that patients. you the

Norbert Riedel

ran different Yes, to function. part process through of I generally, unique Harald disease, in in causes impairment NMDA reduced that few Parkinson's involve function, but cognitive impaired of Parkinson's earlier the rationale and that's results disease, mechanistic think NMDA I not think a neurodegenerative quite the

so I we've that we have plan. clinical impairment. causes that this always broad And remains once remains our think, in concept of different And applicability of cognitive our I proof we multiple, think had and thought area,

Gary Nachman

thank you. Okay,

Norbert Riedel

you. Thank

Operator

Our of next from from line Chris comes Sandler. Raymond question Piper the

line open. Your is

Unidentified Analyst

is Ally Chris question. the this for Thanks on Hi, today. taking for

since program the the of patients just at the that, to other And helpful run you SOBP the of Stage presenting community be point. stood So to or then other on on most PTSD of additional set analysis the in hoping analysis or imbalances XXX characterize at expect can out for since feedback helpful that the see that trial on from some Stage you've related color X was really mechanisms would presented data data adjusting if the on XXX SOBP, additional wondering to to Thanks. aspects any you. analysis and at physician for of just time trauma could we that the for data the that kind to of any what in it baseline trial, X just if the see

Norbert Riedel

Thank you, Ally. Great question.

presented who ask he SOBP actually in one answers, the provides areas to Harald data the I'm going is most actually you with the of meeting. actually So because

you that one. So Harald could if tackle

Harald Murck

in a a time on and you severity as trauma. the know, also presented smaller of our you data I say you if the a course, of randomness, from want mean, CAPS-X poster, just since specific baseline characteristics if Yes, really to analysis, we some of to if and was motivated we're to, course baseline there's a adjustments aren't don't significant the the imbalance by was study perspective, the fell there particularly regarding want as

basically to make compare additional motivated us to to that scientifically do. and We do I this right anything which analysis, with So sure this the think, thing not want we this else. is

a Stage much somewhat imbalances are we in to would treated Stage outcome which makes look that than with, this actively I for the group. didn't meaningful, number much just unfortunate basically in This not the XX were X, X, smaller because ended subjects compound up X up think, come with the any placebo of Stage in conclusive subjects originally XX, order in X, have situation whatever in anticipated XX also Stage underpowered analysis. Regarding is been the resides

data. has structure based in moment this the our time, at and move data would well want exclude post with Regarding you the [Indiscernible] that been I the I verify analysis done. on to justification say quite satisfaction, that additional doing out, analysis, But analysis would say sometimes wouldn't we to are on evidence comes we any to nice based the publication this understand thing. And talk forward a additional same see we

Norbert Riedel

it suffer your an NMDA prefrontal receptor function so to why have to I XXX a and fear, and part, we mechanistically a preclinically, hypo And fear in with cortex kick that known really a the people properly is from of as active PTSD what of activity. can extension. what Ally target PTSD And extinction XXX second well conditioning well indeed And is describes be maybe extinction, is extinguish to really off, area because fear in fear accelerated the that consolidate as consolidation. shown they we that that

offer that to the get this when at of helpful pointing home in as is we in compared they distinction depression addresses have root sufferers. don't underlying I've the therapies out. and symptoms rationale PTSD you course, of important KOHthat That's a really I suffering PTSD, cause today, only or from of that mechanistic have becoming if fear. which makes without the underpinnings what want but people an other to PTSD who approved example, always extinguish don't Harald, and from as people to actually you believe we feedback know two the I to keep So PTSD more of between

Harald Murck

quite Yes, feedback. I to not honest, be don’t much that

regarding to by of touch got feedback in data. a you our this with into This was quite difficult get We ourselves As somewhat a specific with bit nothing getting people. was but KOH contact conference. know, virtual

Norbert Riedel

Okay.

that So answered Ally? question your

Operator

Wainwright. comes Our next from question Selvaraju from the of line HC

line is open. Your

Unidentified Analyst

Thanks Mason Ram Selvaraju. for Hi question. this is for my taking team,

pave modulator licensed TRD Therapeutics. taking depression. NYX-XXX. for about from this came resistant Wondering So negative NYX-XXX indications showing tracking Thanks They've Novartis. you're I was allosteric for a my Cadent it and thinking safety question. precedent if And they're and in a across owned this by for It's MIJ-XXX. treatment could and efficacy

Norbert Riedel

that just played We we we decade and little Yes, a might partnered in on and worth depression of where certainly be with we're that. and acquired. it and program a program aware into the follow then history treatment our has then of definitely Novartis refresher follow

Ashish Khanna

Yes, this Ashish. is

recall of Naurex. predecessor course, that was out one You company of [Indiscernible] our

generated well of As chemistry, disorder, the Naurex IV the in Allergan had XXXX. and two depression, sold IV we back was in The therapeutics different administered sale on we Phase again for compelling DRD. for chemistry, large multiple, in depression. peptidesdemonstrating down across that peptides effects controlled data earlier peptide impetus had depressive treatment X interest studies administered We major

Aptinyx As part those collaboration research of does around area field of engaged Aptinyx some field put and depression. deal, included we restrictions spin that in and a out the restrictions our in on that is Allergan,

be will so the not we into major disorder And in depressive going near-term.

Unidentified Analyst

there. the Okay. I'll back in the Thanks for connecting dots get queue.

Operator

from JPMorgan. comes from Fye Jessica of question line next the Our

open. is line Your

Unidentified Analyst

this here. Hi, for question. Thanks for Jessica. question is One our quick taking Daniel

XXXX. in as in for enrollment readout We the on in track DPN on ongoing Phase other remain studies. know have about you well in prepared as the the mentioned impact Q&A that you heard COVID first I studies remarks to half of X

impact you how curious, with of have have made So the to much amendments an enrollment? helped

Norbert Riedel

Daniel. Yes, to you update. want hand Kathryn, question. quick that great give I to Thanks, to just a

Kathryn King

we as track up, of impact COVID trials. with we've We're as we on think manage way I remain our described. things and Yes, happy are on monitor come they but continue issues the to progressing the

Unidentified Analyst

you. Thank

Operator

the comes next line from Our question Fitzgerald. of Charles Duncan Cantor from

is line open. Your

Norbert Riedel

are Charles, there? you

Charles Duncan

Yes, I mute talking on myself. was to

a the for follow that. Thanks XXX on question about did Sorry questions. two ask actually I taking up. have

and One pursuing. DLB not you're PD study is plan, So that the they're multi part. the on

they up PD within background? movement you Or relative For patients? And are therapy disorder how think on patients, stable wondering dopamine that. I PD to guess are shows the these I'm cognition pre save

Norbert Riedel

I'm Great. up we the opportunity it. as took follow to glad have you the do time to

So hand you. Harald I'm to it to going

Harald Murck

Yes, to These to participate. be we that disorders, that aspects, but people patients patients so movement the disorders, just are can to just regard be who have the indeed, on stable touch medication, although cognitive they have would, these movement be exclusion they an be with from can motor as here stable. have to treated they then allowed will have which assessments, not and would

course, is want, no capability the have focus tests. the that make general those so but if the is in motor cognition, So sure there participate of to and on we between just to dysfunction you you interference

So medication if should out. get to but people be stable, want

Charles Duncan

for rare if as And the it such NPD? you how wondering be. of to kind helpful. you XXX follow those like going applicable there paradigm, or it's yet, that big broadly disorders a are that's time Gaucher driven to question any just how α-synuclein. previous hard a see by have prevalent or are once a are associated seems of disorders neurodevelopmental a highly may beyond I'm patients up may maybe Okay, disorder And then just build benefit And be, really guess, And if signal, long it Parkinson's, and sense with I disorders a positive mechanism to some treat. could GBA perspective XXX more

Norbert Riedel

Yes, it’s great. Thank you, Charles.

about have rare to as of should signal minded of I set be idea we of that And open it very asking that else course. I I or the diseases like we we target. typically signals. then reliable go that’s a think are think established what

to so that a of would Harald that look receptor across at also goes And this we NMDA how go you a can board and Yes, broad likely moment diseases dysfunction question correlation the the mechanism impairment where ago, certainly is ahead. And back of an be? those mentioned between cognitive

Harald Murck

Sorry for that.

even just regard things of in receptor. need NMDA receptors, want I general is terms also like inflammation an down it to that broad indeed mechanism, diabetes regulation that to a down very say So regulation a NMDA to we’ve of in

So I very modifications. we would mechanistically the mechanism [Indiscernible] look this But be to with because place that indeed, the think to generalizable able county's will we believe, much is be at

Charles Duncan

for to the year. signal Wait next Thanks.

Norbert Riedel

Thank you.

Operator

the from question follow line HC We Selvaraju Wainwright, Ram have up a of open. Your line coming from is

Unidentified Analyst

again. Mason is Hi, this

I this readout data follow a NYX-XXX. up coincide was if year in aiming wondering mind? specific with later regarding conference the a you're Just quick to

Norbert Riedel

Yes, look to much scientific appropriate second I But very we the distance presentation a SOBP, are like readout. The half actually would for year data next symposium discussion. and will And discussed clear. away say readout or of for data from the is the medical just suitable the is we that still data be we quite

So set conference Yes, let's consider. then see what like you're the is where we welcome. we logical of and should sort come out of

Operator

comments. for Norbert to Back closing any

Norbert Riedel

day. We of your enjoy and time the attention. Stay the rest appreciate and well your

Operator

joining us. for again you Thank

You may now disconnect.